

NextGen BRCA

Indication



Breast Cancer



Ovarian Cancer



Prostate Cancer



Pancreatic Cancer

Technology



NGS and MLPA

Specimen



Blood (Germline)



Block (Somatic)

TAT



15 days

Why Metropolis?

- ▶ As per NCCN guidelines, when germline testing is clinically indicated, it should be performed in accredited and approved lab
- ▶ Lesser Rejection rate as compared to other Labs (More than 30% rejection rate of others labs due to quantity not sufficient)
- ▶ Metropolis provides interpretation of Various Variant Categorization (Pathogenic, likely Pathogenic and Variant of Unknown significance)
- ▶ As per NCCN guidelines large deletion and duplications should be done concurrently, So comprehensive panel of NGS and MLPA is highly recommended
- ▶ BRCA Germline and Somatic Mutation is useful for therapeutic selection of PARPi
- ▶ Post Result free Genetic counselling
- ▶ Genetic Counsellor keeps a tab on VUS which can get reclassified as Pathogenic or likely pathogenic in future

Test Code	Test/Profile Name	Reported on	Method
B0077	NextGen BRCA Comprehensive (NGS & MLPA), Blood	15th day	NGS & MLPA
B1032	NextGen BRCA Germline, Blood	15th day	NGS
B0075	BRCA deletion/duplication analysis - EDTA Whole blood	15th day	MLPA
B0106	NextGen BRCA Somatic, FFPE tissue	15th day	NGS
B0076	Targeted Mutational Analysis(Family Members)	7th Day	Sanger Sequencing